News | November 23, 2011

Surgical Bypass Strongly Beats Endovascular Treatment as Preferred Treatment of Blocked Blood Vessels in the Femoral Artery

November 23, 2011 – Vascular occlusions are blocked blood vessels caused by a blood clot in an artery. Blocks in the femoral artery are particularly problematic, and vascular surgeons continue to research and debate on the best methods to treat these clots. Results from the THRUPASS Study Group’s randomized controlled trial comparing superficial femoral artery (SFA) lesion treatment with either endoluminal polytetrafluoroethylene (PTFE) thrupass (Viabahn) or with surgical PTFE bypass were presented to attendees at the 38th Annual VEITH symposium in New York City by Mauri J.A. Lepantalo, M.D., Helsinki University Central Hospital, Helsinki, Finland.

In the study, the SFA lesions of the patients were 5-25 cm occlusions, with a mean length of 11.4 cm. The patients were followed for three years by physical exam, duplex ultrasound or other imaging modalities. The endpoint of greatest interest was primary patency, followed by secondary patency, functional success, costs and quality of life. Lepantalo said, “The goal had been to enroll 60 patients in each arm. However, the trial was prematurely terminated due to results at the interim analysis, when only 44 patients had been enrolled. There was a significant patency difference in favor of surgical bypass over endovascular thrupass (95 percent versus 44 percent).”

Lepantalo noted that this was a difficult trial to enroll patients, because the investigators were looking carefully for comparable lesions to which to randomize treatment. “The real problem with comparing different modes of treatment for lower limb ischemia is in controlling for the disease, to ensure that the comparisons are among patients with the same lesions. This is compounded by the fact that different physicians interpreting the same lesions will characterize them differently,” said Lepantalo.

In this study, the results showed that treatment of superficial femoral artery occlusions should be done by PTFE bypass rather than by PTFE thrupass, as the later method leads to a worse early outcome.

For more information: www.VEITHpress.org

Related Content

Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
Overlay Init